Shree Ganesh Remedies Limited Reports Q3 & 9MFY26 Results with 22% YoY Revenue Decline

Shree Ganesh Remedies Limited, a fast-growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q3 & IMFY26. The company faced challenges including delays in shipments, a challenging demand environment in Europe, and heightened competitive intensity, leading to a 22% YoY decline in revenue. Despite this, the company remains focused on execution, capability-building, and driving volume improvement. The new pilot facility is now commissioned, and the expansion programme for Block 7 is progressing as planned. The CRAMS engagement with the Japanese client is also advancing positively. The company expects a gradual improvement in business momentum in FY27.